Sugi Predict

Sugi Predict / Compounds / SCHEMBL1676960

SCHEMBL1676960

SCHEMBL1676960

O=C(O)N1CCC(ON2C(=O)c3ccccc3C2=O)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ MAPK1 P28482 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ KMT2A Q03164 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ SCN1A P35498 2/20 0.38
▸ SCN2A Q99250 2/20 0.38
▸ SCN3A Q9NY46 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ GAA P10253 2/20 0.37
▸ EPHX2 P34913 1/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16611790 0.91 L3MBTL1 (0.45) L3MBTL1MAPK1SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL20237173 0.84 ALDH1A1 (0.43) L3MBTL1MAPK1SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL26931611 0.82 GAA (0.46) L3MBTL1ALDH1A1CYP1A2CYP2C9MAPT
SCHEMBL30728974 0.82 GAA (0.46) L3MBTL1ALDH1A1CYP1A2CYP2C9MAPT
SCHEMBL15208921 0.81 GAA (0.50) L3MBTL1MAPK1SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL1677006 0.81 GPR119 (0.53) L3MBTL1MAPTKMT2AKDM4E
SCHEMBL2181655 0.81 L3MBTL1 (0.47) L3MBTL1ALDH1A1HTT
SCHEMBL15797905 0.81 ALDH1A1 (0.45) MAPK1SMN1; SMN2ALDH1A1CYP1A2CYP2C9
SCHEMBL15333950 0.80 L3MBTL1 (0.39) L3MBTL1MAPK1SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL9388337 0.80 ACHE (0.53) MAPK1ALDH1A1KMT2AMEN1SCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3976185-B1 HECT E3 LIGASE INHIBITORS AND USES THEREOF IFOM ST FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS (IT) 2024-02-14 — — EP disclosed
EP-3976185-A1 HECT E3 LIGASE INHIBITORS AND USES THEREOF IFOM - Fondazione Istituto FIRC di Oncologia Molecolare (IT) 2022-04-06 — — EP disclosed
WO-2020245213-A1 HECT E3 LIGASE INHIBITORS AND USES THEREOF IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) 2020-12-10 — — WO disclosed
US-8518934-B2 Oxycarbamoyl compounds and the use thereof SHONOGI & CO., LTD. (JP) 2013-08-27 — — US disclosed
EP-2346820-B1 OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF SHIONOGI & CO (JP) 2013-02-13 — — EP disclosed
EP-2467383-A1 HETEROCYCLIC OXIME COMPOUNDS Novartis AG (CH) 2012-06-27 — — EP disclosed
US-20110098276-A1 OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2011-04-28 — — US disclosed
WO-2011020861-A1 HETEROCYCLIC OXIME COMPOUNDS NOVARTIS AG (CH) 2011-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098276-A1 OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF CACNA1B, ORAI1, CACNA1I L3MBTL1 3054/4885MAPK1 1446/4885SMN1; SMN2 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.